NasdaqGS:ENDP

Stock Analysis Report

Executive Summary

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally.

Snowflake

Fundamentals

Slightly overvalued with imperfect balance sheet.


Similar Companies

Share Price & News

How has Endo International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

34.9%

ENDP

2.8%

US Pharmaceuticals

1.8%

US Market


1 Year Return

-72.5%

ENDP

-6.5%

US Pharmaceuticals

7.3%

US Market

Return vs Industry: ENDP underperformed the US Pharmaceuticals industry which returned -6.5% over the past year.

Return vs Market: ENDP underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

ENDPIndustryMarket
7 Day34.9%2.8%1.8%
30 Day17.8%1.6%-0.7%
90 Day47.7%0.01%0.06%
1 Year-72.5%-72.5%-4.3%-6.5%9.7%7.3%
3 Year-76.5%-76.5%19.4%11.0%46.3%36.9%
5 Year-92.5%-92.5%25.5%12.3%64.5%46.5%

Price Volatility Vs. Market

How volatile is Endo International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Endo International undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: ENDP ($4.83) is trading below our estimate of fair value ($28.77)

Significantly Undervalued: ENDP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ENDP is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ENDP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ENDP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENDP has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Endo International forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

35.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENDP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ENDP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ENDP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ENDP's revenue is expected to decline over the next 3 years (-1.1% per year).

High Growth Revenue: ENDP's revenue is forecast to decline over the next 3 years (-1.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if ENDP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Endo International performed over the past 5 years?

-22.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ENDP is unprofitable, and losses have increased over the past 5 years at a rate of -22.1% per year.

Accelerating Growth: Unable to compare ENDP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENDP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: ENDP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: ENDP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ENDP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Endo International's financial position?


Financial Position Analysis

Short Term Liabilities: ENDP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ENDP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ENDP has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ENDP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: ENDP has a low level of unsold assets or inventory.

Debt Coverage by Assets: ENDP has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ENDP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ENDP is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -46.6% per year.


Next Steps

Dividend

What is Endo International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ENDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ENDP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ENDP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENDP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Endo International's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Paul Campanelli (57yo)

3.1yrs

Tenure

US$19,970,703

Compensation

Mr. Paul V. Campanelli has been the Chief Executive Officer, President, and Executive Director at Endo International plc since September 23, 2016. Mr. Campanelli joined Endo in 2015 as the President of Par ...


CEO Compensation Analysis

Compensation vs. Market: Paul's total compensation ($USD19.97M) is about average for companies of similar size in the US market ($USD2.67M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.8yrs

Average Tenure

47yo

Average Age

Experienced Management: ENDP's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

5.7yrs

Average Tenure

70yo

Average Age

Experienced Board: ENDP's board of directors are considered experienced (5.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$114,10010 Dec 18
William Montague
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$11.41

Ownership Breakdown


Management Team

  • Terry Coughlin (53yo)

    Executive VP & COO

    • Tenure: 2.9yrs
    • Compensation: US$3.13m
  • Matt Maletta (47yo)

    Executive VP & Chief Legal Officer

    • Tenure: 4.4yrs
    • Compensation: US$2.55m
  • Paul Campanelli (57yo)

    President

    • Tenure: 3.1yrs
    • Compensation: US$19.97m
  • Laure Park

    Senior Vice President of Investor Relations & Corporate Affairs

    • Tenure: 1.2yrs
  • Blaise Coleman (45yo)

    Executive VP & CFO

    • Tenure: 2.8yrs
    • Compensation: US$2.64m
  • Joseph Barbarite

    Executive Vice President of Global Quality and Compliance

    • Tenure: 2.9yrs
  • Mark Bradley

    Senior VP of Corporate Development & Treasurer

    • Tenure: 2.8yrs
  • Susan Williamson

    Senior VP & Chief Compliance Officer

    • Tenure: 1.5yrs
  • Tracy Basso

    Chief Human Resources Officer

    • Tenure: 0.8yrs
  • Jack Boyle (44yo)

    Senior VP of Financial Planning & Analysis Finance

    • Tenure: 0.08yrs

Board Members

  • Michael Hyatt (73yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$315.00k
  • Roger Kimmel (73yo)

    Independent Chairman of the Board

    • Tenure: 5.7yrs
    • Compensation: US$450.00k
  • Bill Montague (72yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$320.00k
  • Shane Cooke (57yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$325.00k
  • Sharad Mansukani (49yo)

    Senior Independent Director

    • Tenure: 1.5yrs
    • Compensation: US$360.00k
  • Nancy Hutson (70yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$320.00k
  • Paul Campanelli (57yo)

    President

    • Tenure: 3.1yrs
    • Compensation: US$19.97m

Company Information

Endo International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Endo International plc
  • Ticker: ENDP
  • Exchange: NasdaqGS
  • Founded: 1920
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.093b
  • Shares outstanding: 226.39m
  • Website: https://www.endo.com

Number of Employees


Location

  • Endo International plc
  • Minerva House
  • First Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENDPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2000
EO7DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2000
ENDP NBMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 2000
0Y5FLSE (London Stock Exchange)YesCommon StockGBUSDJul 2000

Biography

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:36
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.